Optimization and screening of process parameters for the robust co-pyrolytic study of waste motor oil and rice stubble toward sustainable waste-to-fuel generation.

The current study explores the co-pyrolysis of waste motor oil (WMO) and rice stubble in a designed lab-scale pyrolyzer to produce alternative energy fuels. The parameter screening was followed by optimization utilizing the Box-Behnken design (BBD). Reactor temperature (TR), mixing ratio (M), and holding time (t) affected the co-pyro-oil yield substantially. A maximum co-pyro-oil yield of 90.3% was achieved at a TR = 485 °C, t = 12.5 min, and M = 5% rice stubble to waste motor oil, which was further characterized and compared with the commercial diesel fuel properties. The highest research octane number of 76.15 was obtained for the co-pyro-oil (Co-PO), followed by the pyro-oil generated from only waste motor oil (POWMO). Consequently, the paraffin content increased to 64.34 wt% from 27.66 wt % for PO RS. The carbon number varied from C7-C17 for PO WMO and Co-Po, aligning with the diesel fuel requirements. Furthermore, a substantial enrichment in the physio-chemical properties of the produced Co-PO with reduced moisture content and enhancement in higher heating value (HHV) was also noticed. Hence, the generated Co-PO could be utilized as transport-grade fuel.

In-situ and ex-situ co-pyrolysis studies of waste biomass with spent motor oil: Elucidating the role of physical inhibition and mixing ratio to enhance fuel quality.

Simultaneous renewable energy generation is an imperative part of sustainable hazardous waste management. Therefore, the present work explicates the co-pyrolysis of rice stubble (RS) waste biomass and spent motor oil (SMO) to upgrade the obtained bio-oil. Moreover, two different modes, namely, in-situ and ex-situ, were implemented to analyze the effect of physical inhibition. Monothetic analysis approach was followed to determine optimum process conditions. A substantial increment of âˆ¼ 85% was observed in bio-oil yield for RS: SMO (1:1) in-situ operation whilst the only RS biomass pyrolysis. Moreover, the HHV increased by âˆ¼ 2.15 times after co-pyrolysis with a considerable reduction (62.70%) in water content. Consequently, the paraffin content increased to 79.14 vol% with an iso-paraffin index of 0.285. Subsequently, a possible reaction mechanism is also proposed to evaluate results comprehensively. Altogether, the co-pyrolysis of these feedstocks resulted in improved aliphatic content and reduced oxygenates, encouraging its adequacy as an alternate fuel.

Strategic implementation of integrated bioaugmentation and biostimulation for efficient mitigation of petroleum hydrocarbon pollutants from terrestrial and aquatic environment.

Release of petroleum hydrocarbon pollutants poses a serious problem to the terrestrial as well as marine ecosystem. This study investigated and compared the potency of different biodegradation strategies for mitigating total petroleum hydrocarbon (TPH) of petroleum refinery sludge by an integrated action of bioaugmentation and biostimulation vis-à-vis separate bioaugmentation and biostimulation approaches. The implementation of a concomitant bioaugmentation-biostimulation strategy (BABSS) involving the indigenously developed bacterial consortium and poultry litter extract showed the best performance by mitigating the TPH up to 90.3 ±â€¯3.7% in 21 days. The GC-FID analysis confirmed the efficacy of different TPH degradation strategies. The kinetic study of TPH degradation of BABSS resulted first-order with rate 0.11 day-1. Thus, the BABSS proved to be more efficient in degrading TPH in an eco-friendly manner and hence, may pave the way for better management of petroleum hydrocarbon pollutants, while providing a sustainable solution to the disposal of poultry wastes.

Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.

PURPOSE: In this first-in-human, phase I, GVHD prevention trial (NCT02891603), we combine pacritinib (PAC), a JAK2 inhibitor, with sirolimus to concurrently reduce T-cell costimulation via mTOR and IL6 activity. We evaluate the safety of pacritinib when administered with sirolimus plus low-dose tacrolimus (PAC/SIR/TAC) after allogeneic hematopoietic cell transplantation. PATIENTS AND METHODS: The preclinical efficacy and immune modulation of PAC/SIR were investigated in xenogeneic GVHD. Our phase I trial followed a 3+3 dose-escalation design, including dose level 1 (pacritinib 100 mg daily), level 2 (pacritinib 100 mg twice daily), and level 3 (pacritinib 200 mg twice daily). The primary endpoint was to identify the lowest biologically active and safe dose of pacritinib with SIR/TAC (n = 12). Acute GVHD was scored through day +100. Allografts included 8/8 HLA-matched related or unrelated donor peripheral blood stem cells. RESULTS: In mice, we show that dual JAK2/mTOR inhibition significantly reduces xenogeneic GVHD and increases peripheral regulatory T cell (Treg) potency as well as Treg induction from conventional CD4+ T cells. Pacritinib 100 mg twice a day was identified as the minimum biologically active and safe dose for further study. JAK2/mTOR inhibition suppresses pathogenic Th1 and Th17 cells, spares Tregs and antileukemia effector cells, and exhibits preliminary activity in preventing GVHD. PAC/SIR/TAC preserves donor cytomegalovirus (CMV) immunity and permits timely engraftment without cytopenias. CONCLUSIONS: We demonstrate that PAC/SIR/TAC is safe and preliminarily limits acute GVHD, preserves donor CMV immunity, and permits timely engraftment. The efficacy of PAC/SIR/TAC will be tested in our ongoing phase II GVHD prevention trial.

Sarcopenia and low muscle radiodensity associate with impaired FEV1 in allogeneic haematopoietic stem cell transplant recipients.

BACKGROUND: Quantification of skeletal muscle using computed tomography (CT) is accessible using cancer patients' standard oncologic images. Reduced muscle mass may be related to reduced respiratory muscle strength; however, the impact of this on lung functional parameters is not characterized in adult allogeneic haematopoietic stem cell transplant (alloHCT) recipients. METHODS: A consecutive retrospective series (n = 296) of patients who had alloHCT at a comprehensive cancer centre between March 2005 and April 2015 were included. Pre-transplant CT scans were used to quantify skeletal muscle and adipose tissue at the fourth thoracic (T4) and/or third lumbar (L3) level. Tumour and patient characteristics were recorded, including forced expiratory volume in 1 second (FEV1 ) by spirometry. Regression models were created to characterize predictive relationships. RESULTS: A total of 296 patients (♂n = 161; ♀n = 135) were included, all of whom had chest CT as part of standard care; a subset of these (n = 215, 72.6%) also had abdominal CT. Diagnoses were non-Hodgkins lymphoma (n = 165), acute myeloid leukaemia (n = 66), Hodgkin's disease (n = 14), acute lymphocytic leukaemia (n = 14), myelodysplastic syndromes (n = 18), and other (n = 19). In multivariable linear regression adjusted for sex (P < 0.0001), age (P < 0.0001), haematopoietic cell transplantation-specific co-morbidity index (P = 0.010), and parameters of pulmonary function testing (defined by spirometry, P < 0.0001), both T4 muscle index [ß 0.127 (95% confidence interval 0.019; 0.252), P < 0.0001] and T4 muscle radiodensity [ß 0.132 (95% confidence interval 0.087; 0.505), P = 0.006] were independently associated with FEV1 ; disease risk index (P = 0.877) and Karnofsky performance status (P = 0.548) were not associated with FEV1 . Similar conclusions were obtained when L3 muscle index and radiodensity were considered. Unlike T4, L3 muscle index values can be compared with published cut-off values for sarcopenia. Overall rates of sarcopenia were uniformly higher in the HCT population than in age-matched and sex-matched patients with solid tumours [alloHCT ♂64.7% vs. solid tumour ♂56.6% (P < 0.001); alloHCT ♀57.6% vs. solid tumour ♀36.0% (P < 0.001)]. Significant but moderate correlations (P < 0.001) were found for muscle area and radiodensity between L3 and T4, for both men and women; adipose tissue quantity also correlated significantly (P < 0.001) between L3 and T4 for both men and women. CONCLUSIONS: Lumbar or thoracic CT images are useful for body composition assessment in this population and reveal high rates of sarcopenia, similar to those reported in very elderly patients. Reduced muscle mass and radiodensity associate with impaired FEV1 even after adjustment for clinical covariables including co-morbidities, performance status, disease risk, and mild intrinsic pulmonary disease (chronic obstructive pulmonary disease) defined by spirometry.

Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury.

Allogeneic hematopoietic cell transplantation is a potential curative treatment option for various malignant and nonmalignant hematologic disorders. Patients undergoing an allogeneic hematopoietic cell transplant are prescribed immune-suppressant therapies to facilitate hematopoietic donor-cell engraftment and prevent graft-versus-host disease. Drug-drug interactions may occur, owing to exposure to complex multidrug regimens with narrow therapeutic windows and high toxicity profiles. Here, we describe a unique case of a 65-year-old man with poor-risk acute myeloid leukemia who underwent a matched-sibling hematopoietic cell allograft. Sirolimus and tacrolimus were used for graft-versus-host disease prophylaxis. He developed oral thrush requiring treatment with clotrimazole troches, which subsequently resulted in serious renal toxicity attributed to supratherapeutic levels of sirolimus and tacrolimus. Patient renal function improved after temporarily holding both immune suppressants, and administering phenytoin to help induce sirolimus and tacrolimus metabolism. This case highlights sudden and serious toxicities that resulted from clotrimazole-sirolimus and clotrimazole-tacrolimus drug-drug interactions, even when administered topically.